PMID- 38218319
OWN - NLM
STAT- MEDLINE
DCOM- 20240305
LR  - 20240330
IS  - 1938-3207 (Electronic)
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 119
IP  - 3
DP  - 2024 Mar
TI  - Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic 
      conditions - a narrative review.
PG  - 599-627
LID - S0002-9165(24)00005-4 [pii]
LID - 10.1016/j.ajcnut.2024.01.007 [doi]
AB  - Glucagon-like peptide 1 (GLP-1), a gastrointestinal peptide and central mediator 
      of glucose metabolism, is secreted by L cells in the intestine in response to 
      food intake. Postprandial secretion of GLP-1 is triggered by nutrient-sensing via 
      transporters and G-protein-coupled receptors (GPCRs). GLP-1 secretion may be 
      lower in adults with obesity/overweight (OW) or type 2 diabetes mellitus (T2DM) 
      than in those with normal glucose tolerance (NGT), but these findings are 
      inconsistent. Because of the actions of GLP-1 on stimulating insulin secretion 
      and promoting weight loss, GLP-1 and its analogs are used in pharmacologic 
      preparations for the treatment of T2DM. However, physiologically stimulated GLP-1 
      secretion through the diet might be a preventive or synergistic method for 
      improving glucose metabolism in individuals who are OW, or have impaired glucose 
      tolerance (IGT) or T2DM. This narrative review focuses on fasting and 
      postprandial GLP-1 secretion in individuals with different metabolic conditions 
      and degrees of glucose intolerance. Further, the influence of relevant 
      diet-related factors (e.g., specific diets, meal composition, and size, 
      phytochemical content, and gut microbiome) that could affect fasting and 
      postprandial GLP-1 secretion are discussed. Some studies showed diminished 
      glucose- or meal-stimulated GLP-1 response in participants with T2DM, IGT, or OW 
      compared with those with NGT, whereas other studies have reported an elevated or 
      unchanged GLP-1 response in T2DM or IGT. Meal composition, especially the 
      relationship between macronutrients and interventions targeting the microbiome 
      can impact postprandial GLP-1 secretion, although it is not clear which 
      macronutrients are strong stimulants of GLP-1. Moreover, glucose tolerance, 
      antidiabetic treatment, grade of overweight/obesity, and sex were important 
      factors influencing GLP-1 secretion. The results presented in this review 
      highlight the potential of nutritional and physiologic stimulation of GLP-1 
      secretion. Further research on fasting and postprandial GLP-1 concentrations and 
      the resulting metabolic consequences under different metabolic conditions is 
      needed.
CI  - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Huber, Hanna
AU  - Huber H
AD  - Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the 
      University of Gothenburg, Institute of Neuroscience and Physiology, Molndal, 
      Sweden; Department Nutrition and Microbiota, University of Bonn, Institute of 
      Nutrition and Food Science, Bonn, Germany.
FAU - Schieren, Alina
AU  - Schieren A
AD  - Department Nutrition and Microbiota, University of Bonn, Institute of Nutrition 
      and Food Science, Bonn, Germany.
FAU - Holst, Jens Juul
AU  - Holst JJ
AD  - Department of Biomedical Sciences, University of Copenhagen, Faculty of Health 
      and Medical Sciences, Copenhagen, Denmark; The Novo Nordisk Foundation Center for 
      Basic Metabolic Research, University of Copenhagen, Faculty of Health and Medical 
      Sciences, Copenhagen, Denmark.
FAU - Simon, Marie-Christine
AU  - Simon MC
AD  - Department Nutrition and Microbiota, University of Bonn, Institute of Nutrition 
      and Food Science, Bonn, Germany. Electronic address: 
      marie-christine.simon@uni-bonn.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240111
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Insulin)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Glucagon-Like Peptide 1/metabolism
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Glucose Tolerance Test
MH  - Insulin/metabolism
MH  - Blood Glucose/metabolism
MH  - Overweight
MH  - Diet
MH  - Fasting
MH  - *Glucose Intolerance/metabolism
MH  - Obesity
MH  - Postprandial Period/physiology
PMC - PMC10972717
OTO - NOTNLM
OT  - glucagon-like peptide 1
OT  - glucose tolerance
OT  - human
OT  - meal challenge
OT  - postprandial metabolism
OT  - type 2 diabetes mellitus
EDAT- 2024/01/14 12:42
MHDA- 2024/03/05 06:45
PMCR- 2024/01/11
CRDT- 2024/01/13 19:30
PHST- 2023/09/07 00:00 [received]
PHST- 2024/01/03 00:00 [revised]
PHST- 2024/01/09 00:00 [accepted]
PHST- 2024/03/05 06:45 [medline]
PHST- 2024/01/14 12:42 [pubmed]
PHST- 2024/01/13 19:30 [entrez]
PHST- 2024/01/11 00:00 [pmc-release]
AID - S0002-9165(24)00005-4 [pii]
AID - 10.1016/j.ajcnut.2024.01.007 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 2024 Mar;119(3):599-627. doi: 10.1016/j.ajcnut.2024.01.007. Epub 
      2024 Jan 11.